CIPII may be a therapeutic option in patients with severe subcutaneous (SC) insulin resistance, poor glycemic control with high daily insulin requirements, severe hypoglycemia and hypoglycemia unawareness during SC insulin therapy, skin disorders, SC site issues, lipohypertrophy and lipoatrophy (3). This evidence concerns the gene INS and Hypoglycemia.